At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 102 enrolled
Drug / intervention
aMIL +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Study of Autologous Stem Cell Transplantation With Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted May 21, 2013·Updated Jun 29, 2020
In Brief
A Phase 2 clinical trial evaluating aMIL and No aMIL for Multiple Myeloma. Completed, enrolled 102 participants across 1 site.
Detailed Summary
This research is being done to find out if altering the immune system by giving activated marrow infiltrating lymphocytes (MILs) can improve outcomes for multiple myeloma patients who receive a standard autologous stem cell transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsThe Leukemia and Lymphoma Society
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 2013
Enrollment StartSep 2013
Primary CompletionJun 2019
TodayJul 2026
First PostedMay 21, 2013
Enrollment StartSep 1, 2013
Primary CompletionJun 19, 2019
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 13.1 years ago
Interventions
aMILbiological
On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.
No aMILdrug
On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.